Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | DHODH | Q02127 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MLNR | O43193 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1040530 | 0.83 | CES1 (0.40) | CES1NLRP3SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1082547 | 0.80 | KDM4E (0.38) | CES1ALDH1A1LMNAHTTPARP1 | |
| SCHEMBL29424782 | 0.79 | DRD1 (0.39) | CES1PARP1 | |
| SCHEMBL29924184 | 0.79 | DRD1 (0.39) | CES1PARP1 | |
| SCHEMBL665033 | 0.79 | DRD1 (0.39) | CES1PARP1 | |
| SCHEMBL2011321 | 0.79 | ALDH1A1 (0.35) | CES1ALDH1A1 | |
| Iodide SCHEMBL9231386 | 0.78 | DRD1 (0.38) | CES1PARP1 | |
| Iodide SCHEMBL9231383 | 0.78 | DRD1 (0.38) | CES1PARP1 | |
| SCHEMBL9192628 | 0.78 | DRD1 (0.38) | CES1PARP1 | |
| SCHEMBL1044167 | 0.76 | MEN1 (0.43) | CES1ALDH1A1LMNAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1650207-B1 | Process for producing optically active 3-quinuclidinols | TAKASAGO PERFUMERY CO LTD (JP) | 2007-06-27 | — | — | EP | claimed |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | KYOWA PHARMA CHEMICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3950672-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | Kyowa Pharma Chemical Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3199513-B1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-10029968-B2 | Process for producing alcohol analogue | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-9896402-B2 | Method for preventing decrease in optical purity | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| EP-3199513-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | Takasago International Corporation (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9328079-B2 | Process for producing optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9255049-B2 | Ruthenium complex and method for preparing optically active alcohol compounds using the same as a catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-02-09 | — | — | US | disclosed |
| EP-2611819-B1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | TAKASAGO PERFUMERY CO LTD (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-7964744-B2 | Method for producing a ruthenium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20090299076-A1 | Axially asymmetric ester compound and production method thereof | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090227805-A1 | Axially Asymmetric Phosphorus Compound and Production Method Thereof | NATIONAL UNIVERSITY OF CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-2060578-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPHOSPHINYLBUTANOIC ACID | MEIJI SEIKA KAISHA LTD. (JP) | 2009-05-20 | — | — | EP | disclosed |
| US-7462722-B2 | Process for producing optically active-3-quinuclidinols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1650207-B1 | Process for producing optically active 3-quinuclidinols | TAKASAGO PERFUMERY CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1698609-A1 | Process for producing an alcohol or its silyl ether | Takasago International Corporation (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1650207-A1 | Process for producing optically active 3-quinuclidinols | Takasago International Corporation (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20060047122-A1 | Process for producing optically active-3-quinuclidinols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-02 | — | — | US | disclosed |
| US-5587510-A | ASYMMETRICAL HYDROGENATION USING RUTHENIUM-PHOPSHINE COMPLEX AS CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | PTGS1, PTGER1, RACK1 | CES1 1327/4885TRPV1 1010/4885NLRP3 4497/4885 |
| US-20060047122-A1 | Process for producing optically active-3-quinuclidinols | DHPS, QDPR, TYR | CES1 4735/4885TRPV1 2323/4885NLRP3 2813/4885 |
| US-20090299076-A1 | Axially asymmetric ester compound and production method thereof | SQLE, COASY, TBC1D5 | CES1 1903/4885TRPV1 4653/4885NLRP3 4112/4885 |
| US-20090227805-A1 | Axially Asymmetric Phosphorus Compound and Production Method Thereof | BCL2L10, BCL2A1, SOST | CES1 4070/4885TRPV1 3204/4885NLRP3 4697/4885 |
| US-10029968-B2 | Process for producing alcohol analogue | ADH1A, ADH1C, ADH5 | CES1 1128/4885TRPV1 4535/4885NLRP3 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.